Cover Image
市場調查報告書

PharmaPoint:多發性硬化症 (MS) - 全球醫藥品市場預測與市場分析

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 611826
出版日期 內容資訊 英文 343 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:多發性硬化症 (MS) - 全球醫藥品市場預測與市場分析 PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年12月01日 內容資訊: 英文 343 Pages
簡介

主要7個國家(美國,法國,德國,義大利,西班牙,英國,日本) 的多發性硬化症 (MS)的治療藥市場,預計從2016年的147億美元,到2026年擴大到190億美元。預計市場2016年∼2026年以2.9%的年複合成長率成長。

本報告提供多發性硬化症 (MS)的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,促進因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 分類
  • 症狀
  • 預後
  • QOL

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢與轉變
  • 預測手法
  • 流行病學預測
  • 討論

第6章 疾病的管理

  • 診斷概要
  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介:非單株抗體注射療法
  • 產品簡介:單株抗體注射療法
  • 產品簡介:口服療法
  • 其他的疾病修飾藥

第8章 未滿足需求和機會

第9章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的潛力藥物:概要
  • 臨床開發中的潛力藥物:注射療法
  • 臨床開發中的潛力藥物:口服療法
  • 其他

第10章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Biogen
    • Teva
    • Merck Serono (EMD Serono)
    • Sanofi (Genzyme)
    • Bayer
    • Novartis
    • Roche

第11章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

目錄
Product Code: GDHC155PIDR

Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system (CNS) that leads to neurological disability. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action (MOAs). The arrival of novel oral disease-modifying therapies (DMTs) has fulfilled a significant unmet need in the treatment of MS by providing patients with a more convenient route of administration.

With an estimated $14.7B in drug sales, the US dominated the MS market in the 2016 forecast base year, representing around 76.9% of the overall market across the 7MM. We expect the US to remain the leading market throughout the forecast period, generating sales of over $19B in 2026. However, its global market share is expected to decline slightly toabout 76% due to a higher rate of growth in other markets. This dominating position within the 7MM is due to the significantly higher costs of marketed products in the US and the high diagnosed prevalence in the country.

We forecasts that the US will see moderate sales growth over the 10 year forecast period, at a CAGR of around 2.7%, which will be driven by an increase in treatment rates and the introduction of numerous pipeline products offsetting the generic erosion of key brands.

The main drivers of growth in the MS market over the forecast period are -

  • The launch of efficacious pipeline products with convenient oral formulations or less frequent dosing.
  • The continued uptake of oral DMTs, which typically have a higher annual cost of therapy (ACOT) and improved compliance rates.
  • An increase in the number of DMT treatment options that target progressive MS subtypes.

The report "PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2026", provide overview of MS: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In depth, this report provides the following -

  • Annualized MS market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, PPMS and SPMS), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. Promising candidates in Phase IIB or above were profiled.
  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Bayer, Biogen, Merck KGaA, Teva, Sanofi, Novartis.

Scope

  • Overview of MS: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized MS market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, PPMS and SPMS), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. Promising candidates in Phase IIB or above were profiled.
  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 11

2 Executive Summary 12

  • 2.1 Moderate Growth Expected in the MS Market from 2016 to 2026 13
  • 2.2 R&D and Corporate Strategies within the MS Market 14
  • 2.3 Current Treatments Leave a High Level of Unmet Need in the MS Market 16
  • 2.4 Opportunities Remain for Products that Will Fulfill Significant Unmet Needs in the MS Market 17
  • 2.5 Late-Stage Pipeline Drugs Entering the MS Market Will Be a Key Driver of Growth 18
  • 2.6 What Do the Physicians Think? 19

3 Introduction 23

  • 3.1 Catalyst 23
  • 3.2 Related Reports 24

4 Disease Overview 25

  • 4.1 Etiology and Pathophysiology 25
    • 4.1.1 Etiology 25
    • 4.1.2 Pathophysiology 26
  • 4.2 Classification 27
    • 4.2.1 Relapse-Remitting MS 27
    • 4.2.2 Secondary Progressive MS 27
    • 4.2.3 Primary Progressive MS 28
    • 4.2.4 Progressive Relapsing MS 28
  • 4.3 Symptoms 29
  • 4.4 Prognosis 30
  • 4.5 Quality of Life 31

5 Epidemiology 32

  • 5.1 Disease Background 32
  • 5.2 Risk Factors and Comorbidities 32
  • 5.3 Global and Historical Trends 33
  • 5.4 Forecast Methodology 35
    • 5.4.1 Sources 35
    • 5.4.2 Forecast Assumptions and Methods 38
    • 5.4.3 Diagnosed Prevalent Cases of MS 38
    • 5.4.4 Diagnosed Prevalent Cases of MS by Types 42
    • 5.4.5 Diagnosed Incident Cases of MS 44
  • 5.5 Epidemiological Forecast for MS (2016-2026) 47
    • 5.5.1 Diagnosed Prevalent Cases of MS 47
    • 5.5.2 Age-Specific Diagnosed Prevalent Cases of MS 48
    • 5.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 48
    • 5.5.4 Diagnosed Prevalent Cases of MS by Types 49
    • 5.5.5 Diagnosed Incident Cases of MS 50
    • 5.5.6 Age-Specific Diagnosed Incident Cases of MS 51
    • 5.5.7 Sex-Specific Diagnosed Incident Cases of MS 52
  • 5.6 Discussion 53
    • 5.6.1 Epidemiological Forecast Insight 53
    • 5.6.2 Limitation of Analysis 54
    • 5.6.3 Strengths of Analysis 55

6 Disease Management 56

  • 6.1 Diagnosis Overview 56
  • 6.2 Treatment Overview 59
    • 6.2.1 Management of Acute Relapse 60
    • 6.2.2 Treatment with Disease-Modifying Therapies 61
    • 6.2.3 Challenges in Drug Selection as More DMTs Enter the MS Market 61
    • 6.2.4 Shifting MS Treatment Paradigms Unfolding as New DMTs and New Data Become Available 63
    • 6.2.5 Symptomatic Therapies 65
  • 6.3 US 66
    • 6.3.1 Diagnosis 66
    • 6.3.2 Drug Treatment 67
  • 6.4 France 71
    • 6.4.1 Diagnosis 71
    • 6.4.2 Drug Treatment 72
  • 6.5 Germany 74
    • 6.5.1 Diagnosis 74
    • 6.5.2 Drug Treatment 75
  • 6.6 Italy 77
    • 6.6.1 Diagnosis 77
    • 6.6.2 Drug Treatment 77
  • 6.7 Spain 79
    • 6.7.1 Diagnosis 79
    • 6.7.2 Drug Treatment 80
  • 6.8 UK 82
    • 6.8.1 Diagnosis 82
    • 6.8.2 Drug Treatment 83
  • 6.9 Japan 85
    • 6.9.1 Diagnosis 85
    • 6.9.2 Drug Treatment 86

7 Competitive Assessment 89

  • 7.1 Overview 89
  • 7.2 Product Profiles - Non-Monoclonal Antibody Injectable Therapies 91
    • 7.2.1 Betaseron (interferon beta-1b) 91
    • 7.2.2 Avonex (interferon beta-1a) 96
    • 7.2.3 Rebif (interferon beta-1a) 100
    • 7.2.4 Plegridy (pegylated interferon beta-1a) 104
    • 7.2.5 Copaxone (glatiramer acetate) 110
  • 7.3 Product Profiles - Monoclonal Antibody Injectable Therapies 114
    • 7.3.1 Tysabri (natalizumab) 114
    • 7.3.2 Lemtrada (alemtuzumab) 120
    • 7.3.3 Zinbryta (daclizumab) 125
    • 7.3.4 Ocrevus (ocrelizumab) 131
  • 7.4 Product Profiles - Oral Therapies 138
    • 7.4.1 Gilenya (fingolimod) 138
    • 7.4.2 Aubagio (teriflunomide) 143
    • 7.4.3 Tecfidera (dimethyl fumarate) 148
    • 7.4.4 Mavenclad (cladribine) 153
  • 7.5 Other Disease-Modifying Therapies 159
    • 7.5.1 Overview 159

8 Unmet Needs and Opportunity Assessment 160

  • 8.1 Overview 160
  • 8.2 Curative Therapies 161
    • 8.2.1 Unmet Need 161
    • 8.2.2 Gap Analysis 162
    • 8.2.3 Opportunity 163
  • 8.3 Effective Treatments for Progressive MS 163
    • 8.3.1 Unmet Need 163
    • 8.3.2 Gap Analysis 165
    • 8.3.3 Opportunity 166
  • 8.4 The High Cost of MS Drugs 166
    • 8.4.1 Unmet Need 166
    • 8.4.2 Gap Analysis 168
    • 8.4.3 Opportunity 168
  • 8.5 Safety and Tolerability of Therapy 169
    • 8.5.1 Unmet Need 169
    • 8.5.2 Gap Analysis 169
    • 8.5.3 Opportunity 171
  • 8.6 MS Biomarkers for Early Diagnosis and Treatment Choice 171
    • 8.6.1 Unmet Need 171
    • 8.6.2 Gap Analysis 172
    • 8.6.3 Opportunity 172

9 Pipeline Assessment 174

  • 9.1 Overview 174
  • 9.2 Clinical Trial Mapping 175
    • 9.2.1 Clinical Trials by Country 175
  • 9.3 Promising Drugs in Clinical Development - Overview 176
  • 9.4 Promising Drugs in Clinical Development - Injectable Therapies 179
    • 9.4.1 Ofatumumab 179
    • 9.4.2 Ublituximab 186
    • 9.4.3 GnbAC-1 189
    • 9.4.4 Opicinumab 193
    • 9.4.5 ATL-1102 199
  • 9.5 Promising Drugs in Clinical Development - Oral Therapies 203
    • 9.5.1 Siponimod 203
    • 9.5.2 Ozanimod 210
    • 9.5.3 Ponesimod 215
    • 9.5.4 Masitinib 220
    • 9.5.5 ALKS 8700 225
    • 9.5.6 MD1003 229
    • 9.5.7 CHS-131 234
    • 9.5.8 IB-MS 238
    • 9.5.9 Ibudilast 242
    • 9.5.10 Laquinimod 247
    • 9.5.11 Idebenone 254
    • 9.5.12 Evobrutinib 257
  • 9.6 Other Drugs in Development 260

10 Current and Future Players 263

  • 10.1 Overview 263
  • 10.2 Trends in Corporate Strategy 265
  • 10.3 Company Profiles 266
    • 10.3.1 Biogen 266
    • 10.3.2 Teva 269
    • 10.3.3 Merck Serono (EMD Serono) 271
    • 10.3.4 Sanofi (Genzyme) 272
    • 10.3.5 Bayer 274
    • 10.3.6 Novartis 276
    • 10.3.7 Roche 278

11 Market Outlook 280

  • 11.1 Global Markets 280
    • 11.1.1 Forecast 280
    • 11.1.2 Drivers and Barriers - Global Issues 285
  • 11.2 US 286
    • 11.2.1 Forecast 286
    • 11.2.2 Key Events 289
    • 11.2.3 Drivers and Barriers 290
  • 11.3 5EU 290
    • 11.3.1 Forecast 290
    • 11.3.2 Key Events 294
    • 11.3.3 Drivers and Barriers 295
  • 11.4 Japan 295
    • 11.4.1 Forecast 295
    • 11.4.2 Key Events 298
    • 11.4.3 Drivers and Barriers 299

12 Appendix 300

  • 12.1 Bibliography 300
  • 12.2 Abbreviations 319
  • 12.3 Methodology 325
  • 12.4 Forecasting Methodology 325
    • 12.4.1 Diagnosed MS Patients 325
    • 12.4.2 Percent Drug-Treated Patients 326
    • 12.4.3 Launch and Patent Expiry Dates 326
    • 12.4.4 General Pricing Assumptions 327
    • 12.4.5 Individual Drug Assumptions 328
    • 12.4.6 Generic Erosion 334
    • 12.4.7 Pricing of Pipeline Agents 334
  • 12.5 Primary Research - KOLs Interviewed for This Report 336
  • 12.6 Primary Research - Payers Interviewed for This Report 338
  • 12.7 Primary Research - Prescriber Survey 338
  • 12.8 About the Authors 339
    • 12.8.1 Analyst 339
    • 12.8.2 Therapy Area Director 339
    • 12.8.3 Epidemiologist 340
    • 12.8.4 Global Director of Therapy Analysis and Epidemiology 340
    • 12.8.5 Global Head and EVP of Healthcare Operations and Strategy 341
  • 12.9 About GlobalData 342
  • 12.10 Contact Us 342
  • 12.11 Disclaimer 343

List of Tables

  • Table 1: Multiple Sclerosis: Key Metrics in the Seven Major Pharmaceutical Markets 12
  • Table 2: Common Presenting Symptoms of MS 30
  • Table 3: Factors That Can Affect Prognosis in MS 31
  • Table 4: Risk Factors and Comorbidities for MS 33
  • Table 5: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 47
  • Table 6: Revised 2010 McDonald Criteria for the Diagnosis of MS 58
  • Table 7: Treatment Guidelines for MS 60
  • Table 8: Top Three Disease-Modifying Therapies Prescribed for MS by Market 64
  • Table 9: Pharmacotherapy for Common MS Symptoms 66
  • Table 10: US - MS Diagnosis Metrics 67
  • Table 11: US - MS Treatment Metrics 71
  • Table 12: France - MS Diagnosis Metrics 72
  • Table 13: France - MS Treatment Metrics 74
  • Table 14: Germany - MS Diagnosis Metrics 75
  • Table 15: Germany - MS Treatment Metrics 76
  • Table 16: Italy - MS Diagnosis Metrics 77
  • Table 17: Italy - MS Treatment Metrics 79
  • Table 18: Spain - MS Diagnosis Metrics 80
  • Table 19: Spain - MS Treatment Metrics 82
  • Table 20: UK - MS Diagnosis Metrics 83
  • Table 21: UK - MS Treatment Metrics 85
  • Table 22: Japan - MS Diagnosis Metrics 86
  • Table 23: Japan - MS Treatment Metrics 88
  • Table 24: Leading Disease-Modifying Drugs for the Treatment of MS, 2017 91
  • Table 25: Product Profile - Betaseron 93
  • Table 26: Efficacy Results for Betaseron in a Phase III (IFNBMS) Trial 94
  • Table 27: Betaseron SWOT Analysis, 2015 95
  • Table 28: Product Profile - Avonex 97
  • Table 29: Efficacy Results for Avonex in a Phase III Trial 98
  • Table 30: Avonex SWOT Analysis, 2017 99
  • Table 31: Product Profile - Rebif 101
  • Table 32: Rebif SWOT Analysis, 2017 103
  • Table 33: Product Profile - Plegridy 105
  • Table 34: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS 106
  • Table 35: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS 107
  • Table 36: AEs During Year 1 of a Phase III Trial of Plegridy in MS 108
  • Table 37: Plegridy SWOT Analysis, 2017 109
  • Table 38: Product Profile - Copaxone 111
  • Table 39: Copaxone SWOT Analysis, 2017 113
  • Table 40: Product Profile - Tysabri 116
  • Table 41: Efficacy Results for Zinbryta in a Phase III (DECIDE) Trial 117
  • Table 42: Tysabri SWOT Analysis, 2017 119
  • Table 43: Product Profile - Lemtrada 121
  • Table 44: Efficacy Results for Lemtrada in a CARE II Extension Trial 123
  • Table 45: Lemtrada SWOT Analysis, 2017 124
  • Table 46: Product Profile - Zinbryta High-Yield Process 127
  • Table 47: Efficacy Results for Zinbryta in a Phase III (DECIDE) Trial 128
  • Table 48: Summary Safety Data for Zinbryta in a Phase III (DECIDE) Trial 129
  • Table 49: Zinbryta SWOT Analysis, 2017 130
  • Table 50: Product Profile - Ocrevus 133
  • Table 51: Efficacy Results for Ocrevus in a Phase III (OPERA I and OPERA II) MS Trial 134
  • Table 52: Efficacy Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials 134
  • Table 53: Safety Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials 136
  • Table 54: Safety Results for Ocrevus in Phase III (ORATARIO) MS Trials 136
  • Table 55: Ocrevus SWOT Analysis, 2017 137
  • Table 56: Product Profile - Gilenya 140
  • Table 57: Gilenya SWOT Analysis, 2017 142
  • Table 58: Product Profile - Aubagio 144
  • Table 59: Aubagio SWOT Analysis, 2017 147
  • Table 60: Product Profile - Tecfidera 150
  • Table 61: Tecfidera SWOT Analysis, 2015 152
  • Table 62: Product Profile - Mavenclad 155
  • Table 63: Efficacy Results for Mavenclad in a Phase III (CLARITY and CLARITY EXTENSION) MS Trial 156
  • Table 64: Safety Results for Mavenclad in a Phase III (CLARITY) MS Trial 157
  • Table 65: Mavenclad SWOT Analysis, 2017 158
  • Table 66: Summary of Alternative MS DMTs, 2016 159
  • Table 67: Product Profile - Ofatumumab 181
  • Table 68: Efficacy Results for Ofatumumab in a Phase IIB (MIRROR) MS Trial 182
  • Table 69: Safety Results for Ofatumumab in a Phase IIB (MIRROR) MS Trial 183
  • Table 70: Ofatumumab SWOT Analysis, 2017 185
  • Table 71: Product Profile - Ublituximab (TG-1101) 187
  • Table 72: TG-1101 SWOT Analysis, 2017 188
  • Table 73: Product Profile - GnbAC-1 190
  • Table 74: GnbAC-1 SWOT Analysis, 2017 192
  • Table 75: Product Profile - Opicinumab 195
  • Table 76: Efficacy Results for Opicinumab in a Phase IIb (SYNERGY) MS Trial 196
  • Table 77: Opicinumab SWOT Analysis, 2017 199
  • Table 78: Product Profile - ATL-1102 200
  • Table 79: Summary of the Efficacy Results of the Phase IIA trial of ALT-1102 201
  • Table 80: Safety Results of the Phase IIA trial of ALT-1102 202
  • Table 81: ATL-1102 SWOT Analysis, 2017 203
  • Table 82: Product Profile - Siponimod 205
  • Table 83: Safety of Siponimod 207
  • Table 84: Siponimod SWOT Analysis, 2017 209
  • Table 85: Product Profile - Ozanimod 211
  • Table 86: Ozanimod SWOT Analysis, 2017 214
  • Table 87: Product Profile - Ponesimod 216
  • Table 88: Efficacy Results for Ponesimod in a Phase IIb MS Trial 217
  • Table 89: Ponesimod SWOT Analysis, 2015 219
  • Table 90: Product Profile - Masitinib 221
  • Table 91: Masitinib SWOT Analysis, 2017 224
  • Table 92: Product Profile - ALKS 8700 226
  • Table 93: ALKS 8700 SWOT Analysis, 2017 228
  • Table 94: Product Profile - MD1003 230
  • Table 95: Efficacy Results for MD1003 in a Phase III MS-SPI Trial 231
  • Table 96: MD1003 SWOT Analysis, 2017 233
  • Table 97: Product Profile - CHS-131 235
  • Table 98: Efficacy Data from Phase II Study for CHS-131 236
  • Table 99: Efficacy Data from Phase II Study for CHS-131 236
  • Table 100: CHS-131 SWOT Analysis, 2017 237
  • Table 101: Product Profile - IB-MS 239
  • Table 102: Interim Efficacy Results of IB-MS in SPMS and PPMS Patients 240
  • Table 103: IB-MS SWOT Analysis, 2016 241
  • Table 104: Product Profile - Ibudilast 244
  • Table 105: Efficacy Data from Phase II Study for Ibudilast 245
  • Table 106: Safety Data from Phase II Study for Ibudilast 245
  • Table 107: Ibudilast SWOT Analysis, 2017 247
  • Table 108: Product Profile - Laquinimod 250
  • Table 109: Laquinimod SWOT Analysis, 2017 253
  • Table 110: Product Profile - Idebenone 255
  • Table 111: Idebenone SWOT Analysis, 2017 257
  • Table 112: Product Profile - Evobrutinib 258
  • Table 113: Evobrutinib SWOT Analysis, 2017 260
  • Table 114: Drugs in Development, 2017 261
  • Table 115: Key Companies in the MS Market, 2016 264
  • Table 116: Biogen's MS Portfolio Assessment, 2017 268
  • Table 117: Teva's MS Portfolio Assessment, 2017 270
  • Table 118: Merck's MS Portfolio Assessment, 2015 272
  • Table 119: Sanofi's MS Portfolio Assessment, 2017 274
  • Table 120: Bayer's MS Portfolio Assessment, 2015 276
  • Table 121: Novartis' MS Portfolio Assessment, 2017 278
  • Table 122: Roche's MS Portfolio Assessment, 2017 279
  • Table 123: Global MS Market - Drivers and Barriers, 2016-2026 285
  • Table 124 Key Events Impacting Sales for MS in the US, 2016-2026 289
  • Table 125: MS Market in the US - Drivers and Barriers, 2016-2026 290
  • Table 126: Key Events Impacting Sales for MS in the 5EU, 2016-2026 294
  • Table 127: MS Market in the 5EU - Drivers and Barriers, 2016-2026 295
  • Table 128: Key Events Impacting Sales for MS in Japan, 2016-2026 298
  • Table 129: MS Market in Japan - Drivers and Barriers, 2016-2026 299
  • Table 130: Key Launch Dates 326
  • Table 131: Key Patent Expiries 327
  • Table 132: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 338
Back to Top